Novartis has crossed all of the legal hurdles and launched its biosimilar of Neupogen, but its patent fight with Amgen was extended when the Swiss drugmaker asked the U.S. Supreme Court to get involved. In question are a number of issues that are key to Novartis ambitious biosimilars plans going forward; those issues will determine in whose pocket,
Impax Laboratories, Inc. has announced that it entered definitive deals with Teva Pharmaceutical Industries Ltd. and associates of Allergan plc to acquire a wide range of generic products. The deals included solid oral, inhalable, injectable and topical dosage forms and the return of rights to Impax to the company's pending abbreviated new drug...
We look forward to increasing our collaboration with FDA in this area in order to benefit from each other's experiences, and to advance patient involvement. " The currently existing EMA/ FDA clusters discuss issues related to biosimilars, medicines to treat cancer, orphan medicines, medicines for children, and pharmacovigilance, among other topics.
Glenmark Pharmaceuticals Inc., USA has been granted tentative approval by the US Food& Drug Administration for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg, the generic version of Benicar Tablets of Daiichi Sankyo, Inc. Glenmark will market this product upon receiving final approval of its Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg
HERTFORDSHIRE, England and PITTSBURGH, June 24, 2016/ PRNewswire/ Mylan N.V. today announced the U.S. launch of Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart Capsules. Dutasteride Capsules, 0.5 mg, had U.S. sales of approximately $297.2 million for the 12 months ending April 30, 2016, according to IMS Health.
Natoco Pharma ended 3.8% higher after the company clarified to the BSE regarding USFDA approval the company received for generic version of Glycopyrrolate Tablets. "We received from our US agent on 22nd June 2016 intimating the approval for generic version of Glycopyrrolate Tablets 1 mg and 2 mg from US FDA. We have not disclosed the said news to a
The Trans-Pacific Partnership is the most recent multi-national agreement under considerations that may have profound implications in developed and developing countries in the Pacific Rim. " Our news journalists obtained a quote from the research from the University of Maryland, "As in the case of other trade arrangements, the TPP negotiations are
Research Conducted at University of Occupational and Environmental Health Has Provided New Information about Rheumatology. The news reporters obtained a quote from the research from the University of Occupational and Environmental Health, "Notably, rheumatologists will be at the forefront of the use of biosimilar monoclonal antibodies/soluble...
Allergan plc, a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration has approved the company's supplemental New Drug Application to update the label for AVYCAZ with clinical data from a Phase 3 trial evaluating the safety and efficacy of AVYCAZ, in combination with metronidazole, for the treatment of co
Antares Pharma, Inc. today announced that Teva Pharmaceuticals USA, Inc. has settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, LLC relating to AstraZeneca s US Patent Nos. 6,858,576, 6,872,700, 6,956,026, 7,297,761, 6,902,744, 7,521,423, and 7,741,269 and AstraZeneca s BYETTA , a
The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. The report profiles 40 companies including many key and niche players such as- Abbott Laboratories AbbVie, Inc. Allergan plc Bayer Pharma AG Hisamitsu Pharmaceutical Co., Inc. Download the full report:...
Healthcare Global Market Analytics provides strategists, marketers& senior management with the critical information to assess the global healthcare sector.. The total value of the healthcare sector globally in 2015 was around $8500 bn. The dominance of generics post the loss of drug patents has negatively impacted the growth of the overall market b
Natco Pharma was trading higher by 4% to Rs 552, extending its Wednesdays 6% rally on the BSE, after the company announced that it has received US Food and Drug Administration for generic version of Glycopyrrolate tablets. We received from our US agent on 22nd June 2016 intimating the approval for generic version of Glycopyrrolate Tablets 1 mg and
Andrew D Zelenetz, Oncology& Hematology Review, 2016; 12: 22-8 http://doi.org/10. 17925/ OHR.2016.12.01.22. Published recently in Oncology& Hematology Review, the peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz, discusses the fact that the escalating cost of cancer care is placing an increasing burden on healthcare systems worldwide, la
Dublin- Research and Markets has announced the addition of the "Pharmaceutical Excipients Market by Type, Functionality, Formulation- Global Forecast to 2021" report to their offering. The global pharmaceutical excipients market is projected to reach USD 8.1 Billion in 2021 at a CAGR of 6.1% in the forecast period 2016 to 2021.. Emerging markets su
Research and Markets has announced the addition of the "Pharmaceutical Excipients Market by Type, Functionality, Formulation- Global Forecast to 2021" report to their offering. The global pharmaceutical excipients market is projected to reach USD 8.1 Billion in 2021 at a CAGR of 6.1% in the forecast period 2016 to 2021.. Emerging markets such as In
Teva Pharmaceuticals USA, Inc., today announced that they have settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, LLC relating to AstraZeneca s US Patent Nos. 6,858,576, 6,872,700, 6,956,026, 7,297,761, 6,902,744, 7,521,423, and 7,741,269 and AstraZeneca s BYETTA , and entered into
Market Research Reports, Inc. has announced the addition of Vietnam Phamaceutical Report Q2/2016 research report to their website www.MarketResearchReports.comLewes, DE 06/23/2016 With 178 drug manufacturers Vietnam pharmaceutical products mostly focus on simple dosage forms and generic form with lower values and overlapping, and comple
By a News Reporter-Staff News Editor at Biotech Week Alvotech, a powerful player in the field of biopharmaceuticals, announces the opening of a new state-of-the-art facility, dedicated to the development and manufacturing of biosimilar monoclonal antibodies. The opening of this industry leading biologics manufacturing plant marks a significant...
Dublin- Research and Markets has announced the addition of the "Key Pharma News Issue 52" report to their offering. The current unmet medical need in influenza treatment creates a favourable commercial environment for MedImmune to enter. -Sanofi/ Merck To End European Joint Vaccines Operations- Teva Acquisition Of Allergan Generics Edges Closer Wit
The Report Global Cancer Biosimilar Industry 2016 Market Research Report provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.- MarketResearchReports.bizAlbany, NY 06/22/2016 The Global Cancer Biosimilar Industry 2016 Market Research Report is a professional and in-depth study
Studies from C. D'Amore and Colleagues Provide New Data on Biotherapies and Biologicals. According to news originating from Perugia, Italy, by NewsRx correspondents, research stated, "The acceptability of switching between reference drugs and their biosimilars is often disputed. A retrospective drug utilization study was conducted in the Umbria reg
Study Data from H.A. Cuello and Co-Authors Update Knowledge of Immunoglobulins. By a News Reporter-Staff News Editor at Biotech Week Investigators publish new report on Immunology. According to news reporting from Buenos Aires, Argentina, by NewsRx journalists, research stated, "Biosimilars are described as biological products that resemble the s
The decision was taken at a meeting chaired by Prime Minister Narendra Modi. India is recognised as a major generic medicine hub of the world. In 2008, Japanese firm Daiichi Sankyo had bought out the countrys largest drug maker Ranbaxy for USD 4.6 billion.
On June 20, 2016, the United States Court of Appeals for the Federal Circuit denied a request by Mylan Pharmaceuticals, Inc. and Mylan, Inc. for a rehearing of the Court's previous decision to uphold a lower court ruling that Acorda Therapeutics, Inc.' s Abbreviated New Drug Application litigation against Mylan can continue in the District Court of